Clinical Data Transparency Would Counter-Balance Off-Label Promotion – NEJM
This article was originally published in The Pink Sheet Daily
Executive Summary
Giving independent researchers access to patient-level data and requiring public release of clinical study reports would help to offset the weakening of FDA’s oversight caused by industry’s First Amendment victories, a Boston University professor says.
You may also be interested in...
FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks
FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.
FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization
Agency grants two citizen petitions from a coalition of pharma companies requesting greater clarity from FDA, but whether the forthcoming guidances will satisfy industry remains an open question.
FDA Reprint Policy Expands To Clinical Practice Guidelines, Medical Reference Texts
FDA has revised, but not loosened, its 2009 final guidance on good reprint practices for distribution of journal articles on unapproved uses of approved drugs and devices.